WallStSmart

Arm Holdings plc American Depositary Shares (ARM)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 6918% more annual revenue ($327.80B vs $4.67B). NVO leads profitability with a 37.2% profit margin vs 17.2%. ARM appears more attractively valued with a PEG of 2.45. NVO earns a higher WallStSmart Score of 74/100 (B).

ARM

Buy

51

out of 100

Grade: C-

Growth: 6.7Profit: 7.0Value: 3.7Quality: 7.8
Piotroski: 4/9Altman Z: 3.93

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARM3 strengths · Avg: 9.3/10
Market CapQuality
$252.01B10/10

Mega-cap, among the largest globally

Altman Z-ScoreHealth
3.9310/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
26.3%8/10

Revenue surging 26.3% year-over-year

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Areas to Watch

ARM4 concerns · Avg: 2.5/10
PEG RatioValuation
2.454/10

Expensive relative to growth rate

P/E RatioValuation
279.2x2/10

Premium valuation, high expectations priced in

Price/BookValuation
29.1x2/10

Trading at 29.1x book value

EPS GrowthGrowth
-12.3%2/10

Earnings declined 12.3%

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ARM

The strongest argument for ARM centers on Market Cap, Altman Z-Score, Revenue Growth. Profitability is solid with margins at 17.2% and operating margin at 15.4%. Revenue growth of 26.3% demonstrates continued momentum.

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bear Case : ARM

The primary concerns for ARM are PEG Ratio, P/E Ratio, Price/Book. A P/E of 279.2x leaves little room for execution misses.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

ARM carries more volatility with a beta of 3.41 — expect wider price swings.

ARM is growing revenue faster at 26.3% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVO scores higher overall (74/100 vs 51/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arm Holdings plc American Depositary Shares

TECHNOLOGY · SEMICONDUCTORS · USA

Arm Holdings plc architects, develops, and licenses central processing unit products and related technologies for semiconductor companies and original equipment manufacturers rely on to develop products.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?